We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy and Toxicity of Intra-Arterial Cisplatin and Etoposide for Advanced Hepatocellular Carcinoma.
- Authors
Sangro, Bruno; Rios, Raquel; Bilbao, Ignacio; Beloqui, Oscar; Herrero, Jose I.; Quiroga, Jorge; Prieto, Jesus
- Abstract
Objective: To analyze the results of an intra-arterially delivered combination chemotherapy in a group of patients with regionally advanced hepatocellular carcinoma (HCC). Methods: 26 patients with proven locally advanced HCC treated with hepatic artery infusion of cisplatin (20 mg/m[sup 2] , days 1–5) and etoposide (75 mg/m[sup 2] , days 1–5) every 4 weeks were retrospectively studied. Results: In an intention-to-treat analysis, overall and complete response rates were 38 and 7%, respectively. Median duration of response was 5 months. Median survival time was 10 months and survival rates at 6, 12 and 24 months were 53, 33 and 24%, respectively. Survival was significantly longer for responders than for non-responders (median: 13 and 3 months, respectively). There were 4 treatment-related deaths among cirrhotics. Conclusions: Intra-arterial chemotherapy using cisplatin and etoposide seems to have some anti-tumor effect against advanced HCC, although a high rate of life- threatening complications precludes the indication of this regimen at least for patients with non-compensated cirrhosis.Copyright © 2002 S. Karger AG, Basel
- Subjects
CISPLATIN; LIVER cancer; LIVER metastasis; LIVER diseases; ETOPOSIDE; COMBINATION drug therapy
- Publication
Oncology, 2002, Vol 62, Issue 4, p293
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000065059